Moderna says its RSV vaccine is 84% effective in older adults. Health

Moderna says its RSV vaccine is 84% effective in older adults.

 Moderna says its RSV vaccine is 84% effective in older adults;

older man wearing a blue surgical mask looks down at his arm, which bears a bandage as if he’s just gotten an injection

Currently, there are no vaccines approved to prevent RSV. (Image credit: Jasmin Merdan via Getty Images)

Moderna’s experimental respiratory syncytial virus (RSV) vaccine was about 84% effective at protecting older adults from lower respiratory tract disease in a late-stage trial, the drugmaker announced(opens in new tab) Tuesday (Jan. 17). 

Moderna has yet to release the full trial results, but based on the company’s analyses, it plans to submit the vaccine for Food and Drug Administration approval “in the first half of 2023,” the company announced. Separately, the same vaccine is also being tested in children in an ongoing early-stage trial, the statement notes.

RSV most often causes mild, cold-like illnesses, but it can cause severe disease in infants, young children with certain medical conditions, and adults ages 65 and older, especially those with weakened immune systems or chronic heart or lung disease, according to the Centers for Disease Control and Prevention(opens in new tab). There is no approved vaccine to prevent RSV, although several pharmaceutical companies are in the midst of late-stage trials testing vaccines in these high-risk groups.

Share On:

Related Posts

0 Responses

Leave a Reply